Multiple sclerosis-secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three ...
Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...
Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...
Early studies of biotin as a treatment for multiple sclerosis (MS) were promising, showing that it was well tolerated and brought sustained reversal of MS-related disability. More recent studies, ...
Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...
The SPRINT-MS trial was a phase II clinical trial of ibudilast, which is an oral therapy being evaluated for progressive MS. It was a two-year trial evaluated in 255 patients recruited from 28 sites ...
The market size for chronic progressive multiple sclerosis in the leading markets is expected to grow significantly by 2034. The United States accounted for the highest chronic progressive multiple ...
Multiple Sclerosis Explained: Symptoms, Risk Factors & How It’s Treated MONDAY, Nov. 10, 2025 (HealthDay News) — Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...
DENVER (CBS4)- It's a disease without a cure and without an effective treatment. Now researchers from around the globe are teaming up to tackle the progressive form of multiple sclerosis. Anuska Ullal ...
The role of imaging in diagnosing progressive multiple sclerosis (MS) and in assessing prognosis is the subject of a new review. MRI is central in the diagnostic workup of patients suspected of having ...
People with MS of all ages and genders consistently report reduced quality of life relative to the general population, a study reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback